Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ofatumumab as Front-Line Treatment in Elderly, Unfit CLL
NCT01444716Phase 2Completed
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Dec 2011
- Primary completion
- Jun 2020
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of ofatumumab in chronic lymphocytic leukemia (CLL), sponsored by University of Texas MD Anderson Cancer Center. Started Dec 2011; status: completed.
02
Drugs
ofatumumab
03
Conditions
chronic lymphocytic leukemia (CLL)
Beyond the preview
Go deeper on NCT01444716.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01444716.